Romiplostim Prevents Chemotherapy Dose Reductions in Gastrointestinal Cancers

The Clinical Bottleneck of Chemotherapy-Induced Thrombocytopenia

Chemotherapy-induced thrombocytopenia remains a frequent complication of systemic cancer treatment, particularly for patients receiving oxaliplatin-based regimens for gastrointestinal malignancies [1]. When platelet counts drop precipitously, clinicians are routinely forced to delay treatment cycles or reduce chemotherapy doses, which compromises relative dose intensity and worsens oncologic outcomes [2, 1]. While thrombopoietin receptor agonists (agents that stimulate bone marrow megakaryocytes to produce platelets) like romiplostim are well-established for immune thrombocytopenia, their role in managing chemotherapy-induced platelet deficits has historically relied on limited data from single-arm studies and meta-analyses [3, 4]. Although recent clinical guidelines support considering these agents to maintain platelet counts during treatment [5, 4], high-quality randomized data confirming their ability to prevent chemotherapy dose modifications have been lacking. A recent study now offers fresh insights into the use of romiplostim for preserving scheduled cytotoxic regimens in patients with gastrointestinal cancers [6].

Targeting Persistent Thrombocytopenia in Gastrointestinal Cancers

Chemotherapy-induced thrombocytopenia is a common complication associated with bleeding, reduced relative dose intensity (the proportion of the planned chemotherapy dose actually delivered over time), and potentially worse oncologic outcomes. Because no widely available therapies are approved specifically for this condition, clinicians often have to compromise on optimal cancer treatment schedules to allow bone marrow recovery. To evaluate a targeted intervention for this clinical bottleneck, researchers conducted a phase 3, international, double-blind, randomized, placebo-controlled trial funded by Amgen and the Biomedical Advanced Research and Development Authority (ClinicalTrials registry number NCT03362177).

A total of 165 patients underwent randomization. All participants had persistent thrombocytopenia, which the investigators defined as a platelet count of 85×10^9 per liter or less on trial day 1. These patients were actively receiving oxaliplatin-based multiagent cytotoxic chemotherapy for gastrointestinal cancers. The cohort primarily consisted of lower gastrointestinal malignancies, with 75% having colorectal cancer, 13% having gastroesophageal cancer, and 12% having pancreatic cancer. The population also reflected advanced disease states, with stage 4 disease present in 72% of the patients in the romiplostim group and 61% of those in the placebo group. Patients were randomly assigned in a 2:1 ratio to receive either romiplostim (109 patients) or a placebo (56 patients) for three chemotherapy cycles.

The primary end point was the absence of chemotherapy dose modifications induced by low platelets in both the second and third chemotherapy cycles. The researchers strictly defined these modifications as any reduction, delay, omission, or discontinuation of the planned oncologic regimen. By focusing on this endpoint, the trial aimed to determine if romiplostim could successfully maintain the necessary platelet thresholds required for uninterrupted cytotoxic therapy.

Preserving Chemotherapy Dose Intensity

The trial demonstrated a substantial clinical benefit for patients receiving the targeted intervention. Specifically, the percentage of patients with no dose modifications induced by chemotherapy-induced thrombocytopenia was 84% (92 of 109 patients) with romiplostim, compared with 36% (20 of 56 patients) with placebo. For practicing oncologists, this indicates that the vast majority of patients receiving the active drug were able to maintain their planned oxaliplatin-based regimens without requiring dose reductions, delays, omissions, or discontinuations.

The researchers quantified this clinical advantage using robust statistical measures, noting that the difference in dose modifications corresponded to an odds ratio of 10.16 (95% confidence interval [CI], 4.44 to 23.72; P<0.001) and a risk ratio of 2.77 (95% CI, 1.78 to 4.30; P<0.001). These metrics highlight a nearly threefold higher probability of maintaining the scheduled relative dose intensity when patients received the thrombopoietin receptor agonist. Based on these findings, the authors concluded that in this phase 3, placebo-controlled trial, romiplostim was efficacious in treating chemotherapy-induced thrombocytopenia. This provides clinicians with a validated pharmacological strategy to prevent treatment interruptions and preserve the full therapeutic impact of cytotoxic chemotherapy in gastrointestinal malignancies.

Safety Profile and Thromboembolic Risk

When evaluating the safety profile of the intervention, the researchers noted that adverse events of grade 3 or higher occurred in 37% of the patients who received romiplostim and in 22% of the patients who received placebo. The investigators determined that these severe adverse events primarily reflected chemotherapy effects rather than direct toxicity from the thrombopoietin receptor agonist.

Looking specifically at toxicities attributed to the intervention, adverse events considered by the investigator to be related to the study drug occurred in 12% of patients who received romiplostim and in 7% who received placebo. These side effects were generally mild, with the most frequent treatment-related adverse events being nausea (2% in each group) and headache (2% in the romiplostim group). Importantly for clinical practice, none of the treatment-related adverse events were serious or led to death or discontinuation of romiplostim, placebo, or chemotherapy. This suggests that the drug can be safely integrated into existing oxaliplatin-based regimens without compounding treatment-limiting toxicities.

Because thrombopoietin receptor agonists stimulate platelet production, clinicians must monitor for potential clotting complications. In this trial, thromboembolic events occurred in 2% of patients who received romiplostim and in no patients who received placebo. While the absolute rate of these events remained low, physicians prescribing this agent to maintain chemotherapy dose intensity should remain vigilant for signs of thrombosis, particularly in patients with underlying gastrointestinal malignancies who already carry an elevated baseline risk for clotting disorders.

References

1. Peshin S, Dharia A, Takrori E, Kaur J, Thanikachalam K, Iyer R. Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment. Current Oncology. 2025. doi:10.3390/curroncol32080455

2. Gurumurthy G, Kisiel F, Gurumurthy S, Gurumurthy J. Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis.. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2025. doi:10.1177/10781552231219003

3. Sainatham C, Singh S, Agrawal S, et al. Romiplostim for chemotherapy induced thrombocytopenia in solid tumors: A meta-analysis.. Journal of Clinical Oncology. 2024. doi:10.1200/jco.2024.42.16_suppl.e24137

4. Soff GA, Al‐Samkari H, Leader A, Eisen M, Saad H. Romiplostim in chemotherapy‐induced thrombocytopenia: A review of the literature. Cancer Medicine. 2024. doi:10.1002/cam4.7429

5. Griffiths EA, Roy V, Alwan L, et al. NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. Journal of the National Comprehensive Cancer Network. 2022. doi:10.6004/jnccn.2022.0026

6. Al-Samkari H, Muñoz C, Geredeli Ç, et al. Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia.. The New England journal of medicine. 2026. doi:10.1056/NEJMoa2511882